Immunotherapy News and Research

Latest Immunotherapy News and Research

Bladder cancer is one of the top 10 most common forms of cancer in the US

Bladder cancer, most frequently caused by smoking and exposure to carcinogens in the workplace, is one of the top 10 most common forms of cancer in men and women in the U.S. More than 70 percent of bladder cancers are diagnosed in stage T1 or less and have not invaded the muscle layer.

11 Jan 2012

Celldex begins rindopepimut and Avastin Phase 2 combination trial in EGFRvIII-positive GB

Celldex Therapeutics, Inc. today announced that patient screening has initiated in a Phase 2 trial of rindopepimut in combination with Avastin in patients with recurrent epidermal growth factor variant III (EGFRvIII)-positive glioblastoma, called the "ReACT Study."

5 Jan 2012

Antigen Express to move AE37 cancer vaccine into larger clinical trials

Generex Biotechnology Corporation today provided an update to the clinical development & regulatory strategy for its cancer vaccine, AE37.

4 Jan 2012

CSF Aβ42 levels appear to be decreased before patients with MCI develop AD dementia

Cerebrospinal fluid levels of Aβ42 appear to be decreased at least five to 10 years before some patients with mild cognitive impairment develop Alzheimer disease (AD) dementia whereas other spinal fluid levels seem to be later markers of disease, according to a report in the January issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

2 Jan 2012

Additional financing to fund Advaxis' cervical cancer trials

Advaxis, Inc.,, a leader in developing the next generation of immunotherapies for cancer and infectious diseases, has entered into a definitive Convertible Notes Purchase Agreement (Agreement) with certain accredited investors, for the purchase of the aggregate principal value of approximately $1.2 million of Convertible Promissory Notes (Notes) for an aggregate purchase price of approximately $1.0 million.

31 Dec 2011

CEL-SCI to expand Multikine Phase III trial in head and neck cancer

CEL-SCI Corporation is in the process of expanding its Phase III clinical trial of the investigational therapy Multikine (Leukocyte Interleukin, Injection) to 4 additional European countries - Spain, Czech Republic, Slovakia and Croatia.

27 Dec 2011

CEL-SCI reports net loss of $26.8M for fiscal year ended September 30, 2011

CEL-SCI Corporation reported financial results today for the fiscal year ended September 30, 2011.

26 Dec 2011

Bloomberg TV to air segment on Antigen Express' immunotherapeutic breast cancer vaccine

Generex Biotechnology Corporation today announced that Bloomberg Television is scheduled to air a segment on the immunotherapeutic breast cancer vaccine being developed by its wholly-owned subsidiary, Antigen Express, Inc.

19 Dec 2011

JHN to initiate new Phase I immunotherapy trial in glioblastoma

Physicians at the Jefferson Hospital for Neuroscience (JHN), the region's only dedicated hospital for neuroscience, are tackling a particularly aggressive brain cancer that even surgery, chemotherapy and radiation often fail to treat with a promising new immunotherapy to attack a patient's tumor with their own cancer cells.

15 Dec 2011

Promising results from Fate Therapeutics' ProHema Phase 1b trial on hematologic malignancies

Fate Therapeutics, Inc. announced today promising clinical results from a Phase 1b trial of ProHema (FT1050-enhanced umbilical cord blood) as part of double-umbilical cord blood (UCB) transplants in adult patients with hematologic malignancies who have undergone reduced-intensity conditioning therapy.

14 Dec 2011

ImmusanT secures $20M in Series A financing

ImmusanT, Inc. announced today it has raised $20 million in Series A financing from Vatera Healthcare Partners LLC to advance development of the biotechnology company's immunotherapeutic vaccine Nexvax2, companion diagnostic and monitoring tool for celiac disease.

14 Dec 2011

Scientists create antigenic myeloma peptide 'cocktail'

Scientists at Dana-Farber Cancer Institute have created a "cocktail" of immune-stimulating peptides they believe could provoke the body's defenses to attack multiple myeloma in its early "smoldering" phase and slow or prevent the blood cancer.

13 Dec 2011

Technique expands scarce resources used for cord blood transplant procedure

A new method to boost the number of immune cells in umbilical cord blood prior to cord blood transplants for cancer patients appears to lead to a quicker rebuilding of a new immune system in the patient's body than with a conventional cord blood transplant procedure, according to new research from the Perelman School of Medicine at the University of Pennsylvania that will be presented today at the 53rd American Society of Hematology Annual Meeting.

12 Dec 2011

Memgen to present ISF35 clinical trial data on CLL at 53rd ASH meeting

Memgen, LLC announces the following abstract on ISF35, the Company's lead product, will be presented during the 53rd Annual Meeting of the American Society of Hematology (ASH) in San Diego, CA.

12 Dec 2011

Galectin Therapeutics to initiate GM-CT-01 Phase 1/2 combination study in advanced MM

Galectin Therapeutics, the Cancer Centre at the Cliniques universitaires Saint-Luc and the Ludwig Institute for Cancer Research (LICR) announced today that they will initiate a Phase 1/2 safety and efficacy trial testing a novel treatment combination in patients with advanced metastatic melanoma.

9 Dec 2011

Milk powder outperforms lower-dose therapy for treatment of food allergies

A small study by researchers at the Johns Hopkins Children's Center and Duke University shows that eating higher doses of milk protein in the form of dry powder substantially outperforms lower-dose therapy — a few drops of liquid milk extract under the tongue — for treatment of food allergies.

7 Dec 2011

Body's surveillance for cancer causing damage and response to allergies share common pathway

CANCER RESEARCH UK scientists have found that the body's surveillance for cancer causing damage and its response to allergies share a common pathway, according to research published in Science on Thursday.

1 Dec 2011

Celldex launches rindopepimut Phase 3 trial in EGFRvIII-positive glioblastoma

Celldex Therapeutics, Inc. today announced that it has launched a pivotal, randomized, double-blind, controlled Phase 3 trial of rindopepimut in patients with surgically resected epidermal growth factor variant III (EGFRvIII)-positive glioblastoma, the "ACT IV Study."

1 Dec 2011

Compugen's Antibody Target Discovery Platform presented at 7th Annual European Antibody Congress

Speaking today at the plenary session of the 7th Annual European Antibody Congress in Geneva, Dr. Anat Cohen-Dayag, President and CEO of Compugen Ltd., presented Compugen's Antibody Target Discovery Platform, one of the Company's predictive discovery platforms for novel therapeutic targets.

1 Dec 2011

Idera regains global rights to IMO-2055 from Merck KGaA for treatment of cancer

Idera Pharmaceuticals, Inc. today announced that it has regained global rights to IMO-2055, an agonist of Toll-like Receptor (TLR) 9, as part of an agreed-upon termination of its oncology collaboration with Merck KGaA, Darmstadt, Germany.

1 Dec 2011

Immunotherapy News and Research

Latest Immunotherapy News and Research

Bladder cancer is one of the top 10 most common forms of cancer in the US

Celldex begins rindopepimut and Avastin Phase 2 combination trial in EGFRvIII-positive GB

Antigen Express to move AE37 cancer vaccine into larger clinical trials

CSF Aβ42 levels appear to be decreased before patients with MCI develop AD dementia

Additional financing to fund Advaxis' cervical cancer trials

CEL-SCI to expand Multikine Phase III trial in head and neck cancer

CEL-SCI reports net loss of $26.8M for fiscal year ended September 30, 2011

Bloomberg TV to air segment on Antigen Express' immunotherapeutic breast cancer vaccine

JHN to initiate new Phase I immunotherapy trial in glioblastoma

Promising results from Fate Therapeutics' ProHema Phase 1b trial on hematologic malignancies

ImmusanT secures $20M in Series A financing

Scientists create antigenic myeloma peptide 'cocktail'

Technique expands scarce resources used for cord blood transplant procedure

Memgen to present ISF35 clinical trial data on CLL at 53rd ASH meeting

Galectin Therapeutics to initiate GM-CT-01 Phase 1/2 combination study in advanced MM

Milk powder outperforms lower-dose therapy for treatment of food allergies

Body's surveillance for cancer causing damage and response to allergies share common pathway

Celldex launches rindopepimut Phase 3 trial in EGFRvIII-positive glioblastoma

Compugen's Antibody Target Discovery Platform presented at 7th Annual European Antibody Congress

Idera regains global rights to IMO-2055 from Merck KGaA for treatment of cancer

Event guide: 7th Allogeneic Cell Therapies Summit eBook

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Immunotherapy News and Research

Latest Immunotherapy News and Research

Event guide: 7th Allogeneic Cell Therapies Summit eBook

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Newsletters you may be interested in